An SGLT2 inhibitor
Related Products
Labeled Version(s)
22369Empagliflozin-d4
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Empagliflozin

Item No. 17375

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol
CAS Number
864070-44-0
Synonyms
  • BI 10773
Molecular Formula
C23H27ClO7
Formula Weight
450.9
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH 7.2) (1:1): 0.5 mg/ml
λmax
224 nm
SMILES
ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC=C(O[C@@H]4COCC4)C=C3
InChi Code
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
InChi Key
OBWASQILIWPZMG-QZMOQZSNSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $29

    Add

    10 mg

    $55

    Add

    50 mg

    $116

    Add

    100 mg

    $145

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 3.1 nM for the human transporter).1 It is selective for SGLT2 over SGLT1, -4, -5, and -6 (IC50s = 8.3, 11, 1.1, and 2 µM, respectively). Dietary administration of empagliflozin (0.03% for 10 weeks) reduces non-fasting blood glucose levels, as well as aortic superoxide levels and cardiac interstitial fibrosis, in db/db mice.2 It also decreases the severity of glomerulosclerosis, as well as reduces the escape latency in the Morris water maze, in the same model. Formulations containing empagliflozin have been used in the treatment of type 2 diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose contransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14(1), 83-90 (2012).

    2. Lin, B., Koibuchi, N., Hasegawa, Y., et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc. Diabetol. 13, 148 (2014).

    Product Citations

    Kaur, N., Ruiz-Velasco, A., Raja, R., et al. Paracrine signal emanating from stressed cardiomyocytes aggravates inflammatory microenvironment in diabetic cardiomyopathy. iScience 25(3), 103973 (2022).